"Qompium is the result of a thesis of my co-founders, says Bieke van Gorp, one of the founders. "In 2014 they were investigating whether it was possible to measure atrial fibrillation via smart phones, for which they collaborated with the Mobile Health Unit of the University of Hasselt Oos-Limburg."
20% of all strokes arises from atrial fibrillation. And 75% of them could have been avoided if it had been determined in time. But that is precisely the problem, there are little to no perceptible symptoms. The physician only listens for a minute and arrhythmia are not constant, so this perception is not always reliable. By screening cardiac patients earlier the number of strokes caused by atrial fibrillation can be reduced drastically. "And do not forget: patients who have undergone surgery can be monitored better and faster," said Van Gorp.
"The app is a huge added value for the cardiologist, because he is the one who prescribes the app. Through the online platform that comes with the application, they can follow the measurements per patient closely. FibriCheck can therefore safely be regarded as an innovative product in a fairly traditional market. Not only can the disorders be evaluated over a longer period of time, in addition, there is no other application that can do the same. "
In the current pilot FibriCheck is tested in three hospitals. "The response has been extremely positive," says Van Gorp satisfied. There are discussions on the international market to have the app launch internationally. "The challenge will be to meet the medical formalities in different countries," Van Gorp says.
20% of all strokes arises from atrial fibrillation. And 75% of them could have been avoided if it had been determined in time. But that is precisely the problem, there are little to no perceptible symptoms. The physician only listens for a minute and arrhythmia are not constant, so this perception is not always reliable. By screening cardiac patients earlier the number of strokes caused by atrial fibrillation can be reduced drastically. "And do not forget: patients who have undergone surgery can be monitored better and faster," said Van Gorp.
Professional public
"Actually, we have deliberately chosen a difficult path, where we had to apply for CE accreditation," says Bieke van Gorp, "because many developers dump their app in the consumer market. Of course, we do have some competitors, but they are not medically validated. ""The app is a huge added value for the cardiologist, because he is the one who prescribes the app. Through the online platform that comes with the application, they can follow the measurements per patient closely. FibriCheck can therefore safely be regarded as an innovative product in a fairly traditional market. Not only can the disorders be evaluated over a longer period of time, in addition, there is no other application that can do the same. "
In the current pilot FibriCheck is tested in three hospitals. "The response has been extremely positive," says Van Gorp satisfied. There are discussions on the international market to have the app launch internationally. "The challenge will be to meet the medical formalities in different countries," Van Gorp says.
